Researchers found that the immune enzyme TYK2 adds a tag to tau protein, causing toxic buildup in the brain. Blocking TYK2 reduced harmful tau and neuron damage in mice, offering a potential new target for Alzheimer’s treatment. #Alzheimers #BrainHealth #Neuroscience #TYK2 #TauProtein
Brain health: Immune enzyme linked to toxic tau buildup in Alzheimer’s disease
Researchers found that the immune enzyme TYK2 adds a tag to tau protein, causing toxic buildup in the brain. Blocking TYK2 reduced harmful tau and neuron damage in mice, offering a potential new target for Alzheimer’s treatment.
www.psypost.org
January 12, 2025 at 7:11 PM
Researchers found that the immune enzyme TYK2 adds a tag to tau protein, causing toxic buildup in the brain. Blocking TYK2 reduced harmful tau and neuron damage in mice, offering a potential new target for Alzheimer’s treatment. #Alzheimers #BrainHealth #Neuroscience #TYK2 #TauProtein
Novel TYK2 inhibitor Zasocitinib
Interest in TYK2, part of the JAK family, is rising due to the success of JAK inhibitors in rheumatic disease treatment. TYK2 is vital for immune activation but has limited roles in metabolic and hematopoietic pathways.
https://buff.ly/3VdI5rV
Interest in TYK2, part of the JAK family, is rising due to the success of JAK inhibitors in rheumatic disease treatment. TYK2 is vital for immune activation but has limited roles in metabolic and hematopoietic pathways.
https://buff.ly/3VdI5rV
Novel TYK2 inhibitor Zasocitinib | RheumNow
Similar to JAKs, TYK2 is an important mediator of innate and adaptive immune activation. Unlike JAKs, however, TYK2 is thought to play a minimal role in other pathways, such as metabolic and…
buff.ly
December 2, 2024 at 8:00 PM
Novel TYK2 inhibitor Zasocitinib
Interest in TYK2, part of the JAK family, is rising due to the success of JAK inhibitors in rheumatic disease treatment. TYK2 is vital for immune activation but has limited roles in metabolic and hematopoietic pathways.
https://buff.ly/3VdI5rV
Interest in TYK2, part of the JAK family, is rising due to the success of JAK inhibitors in rheumatic disease treatment. TYK2 is vital for immune activation but has limited roles in metabolic and hematopoietic pathways.
https://buff.ly/3VdI5rV
TYK2 inhibition enhances Treg differentiation and function while preventing Th1 and Th17 differentiation
@cp-cellrepmed.bsky.social
@mklevings.bsky.social
cell.com/cell-reports...
@cp-cellrepmed.bsky.social
@mklevings.bsky.social
cell.com/cell-reports...
August 19, 2025 at 8:30 PM
TYK2 inhibition enhances Treg differentiation and function while preventing Th1 and Th17 differentiation
@cp-cellrepmed.bsky.social
@mklevings.bsky.social
cell.com/cell-reports...
@cp-cellrepmed.bsky.social
@mklevings.bsky.social
cell.com/cell-reports...
Deep mutational scanning reveals pharmacologically relevant insights into TYK2 signaling and disease
Deep mutational scanning reveals pharmacologically relevant insights into TYK2 signaling and disease
A comprehensive mutational scan of TYK2 identifies novel allosteric sites, elucidates functional drug-protein interactions, and links autoimmune disease protection to reduced TYK2 protein abundance.
buff.ly
July 19, 2026 at 11:26 AM
Deep mutational scanning reveals pharmacologically relevant insights into TYK2 signaling and disease
Novel TYK2 inhibitor Zasocitinib
Interest in TYK2, part of the JAK family, is rising due to the success of JAK inhibitors in rheumatic disease treatment. TYK2 is vital for immune activation but has limited roles in metabolic and hematopoietic pathways.
https://buff.ly/3VdI5rV
Interest in TYK2, part of the JAK family, is rising due to the success of JAK inhibitors in rheumatic disease treatment. TYK2 is vital for immune activation but has limited roles in metabolic and hematopoietic pathways.
https://buff.ly/3VdI5rV
Novel TYK2 inhibitor Zasocitinib | RheumNow
Similar to JAKs, TYK2 is an important mediator of innate and adaptive immune activation. Unlike JAKs, however, TYK2 is thought to play a minimal role in other pathways, such as metabolic and…
buff.ly
December 8, 2024 at 1:03 AM
The FDA has approved brepocitinib as a TYK2/JAK1 inhibitor from Roivant/Priovant
Huge shout out to the #PfizerChemistry team who discovered the molecule - it was a large project team and when I joined the mol had already been identified and…
#ChemSky 1/…
Huge shout out to the #PfizerChemistry team who discovered the molecule - it was a large project team and when I joined the mol had already been identified and…
#ChemSky 1/…
August 28, 2026 at 4:29 PM
The FDA has approved brepocitinib as a TYK2/JAK1 inhibitor from Roivant/Priovant
Huge shout out to the #PfizerChemistry team who discovered the molecule - it was a large project team and when I joined the mol had already been identified and…
#ChemSky 1/…
Huge shout out to the #PfizerChemistry team who discovered the molecule - it was a large project team and when I joined the mol had already been identified and…
#ChemSky 1/…
Mepolizumab treatment in a child with inherited TYK2 deficiency. New report from Aurélia Alimi, TYK2-consortium, Stephanie Wanin, Stephanie Boisson-Dupuis, and Paul Bastard @hopitalnecker.bsky.social @casanovalab.bsky.social: rupress.org/jhi/article/...
#InbornErrorsOfImmunity
#InbornErrorsOfImmunity
August 5, 2025 at 2:31 PM
Mepolizumab treatment in a child with inherited TYK2 deficiency. New report from Aurélia Alimi, TYK2-consortium, Stephanie Wanin, Stephanie Boisson-Dupuis, and Paul Bastard @hopitalnecker.bsky.social @casanovalab.bsky.social: rupress.org/jhi/article/...
#InbornErrorsOfImmunity
#InbornErrorsOfImmunity
Mepolizumab treatment in a child with inherited TYK2 deficiency url: rupress.org/jhi/article/...
Mepolizumab treatment in a child with inherited TYK2 deficiency | Journal of Human Immunity | Rockefeller University Press
We report the case of a patient with complete TYK2 deficiency and virally induced hypereosinophilia and respiratory failure who responded to IL-5 blockade.
rupress.org
July 29, 2025 at 4:24 PM
Mepolizumab treatment in a child with inherited TYK2 deficiency url: rupress.org/jhi/article/...
Deep mutational scanning reveals pharmacologically relevant insights into TYK2 signaling and disease
Deep mutational scanning reveals pharmacologically relevant insights into TYK2 signaling and disease
A comprehensive mutational scan of TYK2 identifies novel allosteric sites, elucidates functional drug-protein interactions, and links autoimmune disease protection to reduced TYK2 protein abundance.
buff.ly
July 19, 2026 at 10:28 PM
Deep mutational scanning reveals pharmacologically relevant insights into TYK2 signaling and disease
Phase 2 trial: ICP-332, a TYK2 inhibitor, showed safety and efficacy for moderate-severe AD in 18-75yr olds across 19 centers in China. PMID:41533373, JAMA Dermatol 2026 https://doi.org/10.1001/jamadermatol.2025.5295 #Medsky #Pharmsky #RNA #ASHG #ESHG 🧪
https://doi.org/10.1001/jamadermatol.2025.5295
No description available
doi.org
January 16, 2026 at 3:10 AM
Hope is still blowing in #SjögrensDisease at #EULAR26!
OP0160
TYK2 inhibition signature is shared in #SLE and #SjD 🔬
TYK2 inhibition signature is associated with disease activity 🔥
Let's wait for the results of the phase 3 trials of TYK inhibition in both diseases ⏳
OP0160
TYK2 inhibition signature is shared in #SLE and #SjD 🔬
TYK2 inhibition signature is associated with disease activity 🔥
Let's wait for the results of the phase 3 trials of TYK inhibition in both diseases ⏳
June 4, 2026 at 8:12 AM
Hope is still blowing in #SjögrensDisease at #EULAR26!
OP0160
TYK2 inhibition signature is shared in #SLE and #SjD 🔬
TYK2 inhibition signature is associated with disease activity 🔥
Let's wait for the results of the phase 3 trials of TYK inhibition in both diseases ⏳
OP0160
TYK2 inhibition signature is shared in #SLE and #SjD 🔬
TYK2 inhibition signature is associated with disease activity 🔥
Let's wait for the results of the phase 3 trials of TYK inhibition in both diseases ⏳
Nat Comm Birgit Strobl Lab
TYK2 KO Mice more resistant to Candida infections—layer of necrotic neutrophils forms around the fungal pathogens to contain them
Interesting since TYK2 inhibitors already approved for psoriatic arthritis, e.g. deucravacitinib (Sotyktu)
www.nature.com/articles/s41...
TYK2 KO Mice more resistant to Candida infections—layer of necrotic neutrophils forms around the fungal pathogens to contain them
Interesting since TYK2 inhibitors already approved for psoriatic arthritis, e.g. deucravacitinib (Sotyktu)
www.nature.com/articles/s41...
December 4, 2024 at 6:35 PM
Nat Comm Birgit Strobl Lab
TYK2 KO Mice more resistant to Candida infections—layer of necrotic neutrophils forms around the fungal pathogens to contain them
Interesting since TYK2 inhibitors already approved for psoriatic arthritis, e.g. deucravacitinib (Sotyktu)
www.nature.com/articles/s41...
TYK2 KO Mice more resistant to Candida infections—layer of necrotic neutrophils forms around the fungal pathogens to contain them
Interesting since TYK2 inhibitors already approved for psoriatic arthritis, e.g. deucravacitinib (Sotyktu)
www.nature.com/articles/s41...
@jem.org a new type I IFN–dependent psoriasis subtype resulting from rare heterozygous variants in ADAR1 and associated with a specific response to JAK1 and TYK2 inhibitors @inserm.fr
rupress.org/jem/article-...
rupress.org/jem/article-...
July 15, 2026 at 6:03 PM
@jem.org a new type I IFN–dependent psoriasis subtype resulting from rare heterozygous variants in ADAR1 and associated with a specific response to JAK1 and TYK2 inhibitors @inserm.fr
rupress.org/jem/article-...
rupress.org/jem/article-...
Tyk2-Inhibitor Marktanalyse und Prognose 2032 | WiseGuyReports www.wiseguyreports.com/de/reports/t...
Tyk2-Inhibitor Marktanalyse und Prognose 2032
Es wird erwartet, dass die Marktgröße für Tyk2-Inhibitoren von 0,04 Milliarden US-Dollar im Jahr 2024 auf 11,0 Milliarden US-Dollar im Jahr 2032 wachsen wird. Der Tyk2-Inhibitor Die Markt-CAGR (Wachst...
www.wiseguyreports.com
September 27, 2026 at 2:19 PM
Tyk2-Inhibitor Marktanalyse und Prognose 2032 | WiseGuyReports www.wiseguyreports.com/de/reports/t...
RRIDs were included in this in eLife paper. Thanks for making your methods matter! #OpenResearch #ReproducibleResearch #OpenScience
Deep mutational scanning reveals pharmacologically relevant insights into TYK2 signaling and disease
A comprehensive mutational scan of TYK2 identifies novel allosteric sites, elucidates functional drug-protein interactions, and links autoimmune disease protection to reduced TYK2 protein abundance.
doi.org
June 15, 2026 at 7:00 AM
RRIDs were included in this in eLife paper. Thanks for making your methods matter! #OpenResearch #ReproducibleResearch #OpenScience
Follow-up re:celebration of fundamentally unroastable @luketimmerman.bsky.social:
-Amazing colleagues we have in Boston biotech ecosystem! @jmaraganore.bsky.social @jeremymax.bsky.social V Sato...
- @jebkeiper.bsky.social =fully caffeinated
-If TYK2 fails, Andy Plump has bright future as toastmaster
-Amazing colleagues we have in Boston biotech ecosystem! @jmaraganore.bsky.social @jeremymax.bsky.social V Sato...
- @jebkeiper.bsky.social =fully caffeinated
-If TYK2 fails, Andy Plump has bright future as toastmaster
March 7, 2025 at 1:02 PM
Follow-up re:celebration of fundamentally unroastable @luketimmerman.bsky.social:
-Amazing colleagues we have in Boston biotech ecosystem! @jmaraganore.bsky.social @jeremymax.bsky.social V Sato...
- @jebkeiper.bsky.social =fully caffeinated
-If TYK2 fails, Andy Plump has bright future as toastmaster
-Amazing colleagues we have in Boston biotech ecosystem! @jmaraganore.bsky.social @jeremymax.bsky.social V Sato...
- @jebkeiper.bsky.social =fully caffeinated
-If TYK2 fails, Andy Plump has bright future as toastmaster
Exclusive: AI unicorn Formation Bio licensed Lynk Pharma’s TYK2 inhibitor for use outside China and plans to take it into Phase 1 next year in a novel disease area.
Exclusive: AI unicorn Formation Bio licenses a TYK2 drug from China
Formation has acquired the ex-China rights to a central nervous system-penetrant TYK2 inhibitor from Lynk Pharmaceuticals.
endpoints.news
December 10, 2025 at 4:41 PM
Exclusive: AI unicorn Formation Bio licensed Lynk Pharma’s TYK2 inhibitor for use outside China and plans to take it into Phase 1 next year in a novel disease area.
Treatment-resistant dermatomyositis improved significantly with the investigational TYK2/JAK1 inhibitor brepocitinib, according to a randomized trial.
https://www.medpagetoday.com/meetingcoverage/aad/120546
https://www.medpagetoday.com/meetingcoverage/aad/120546
Resistant Dermatomyositis Improves Quickly, Significantly With Combination Drug
Brepocitinib significantly boosts global, all secondary dermatomyositis scores in VALOR trial
www.medpagetoday.com
March 30, 2026 at 11:48 PM
Treatment-resistant dermatomyositis improved significantly with the investigational TYK2/JAK1 inhibitor brepocitinib, according to a randomized trial.
https://www.medpagetoday.com/meetingcoverage/aad/120546
https://www.medpagetoday.com/meetingcoverage/aad/120546
Extracellular matrix rigidity controls breast cancer metastasis via TYK2-mediated mechanotransduction https://www.biorxiv.org/content/10.1101/2025.10.30.681251v1
October 31, 2025 at 8:48 AM
Extracellular matrix rigidity controls breast cancer metastasis via TYK2-mediated mechanotransduction https://www.biorxiv.org/content/10.1101/2025.10.30.681251v1
Deep mutational scanning reveals pharmacologically relevant insights into TYK2 signaling and disease https://www.biorxiv.org/content/10.1101/2025.10.11.681520v1
October 13, 2025 at 4:33 AM
Deep mutational scanning reveals pharmacologically relevant insights into TYK2 signaling and disease https://www.biorxiv.org/content/10.1101/2025.10.11.681520v1
Thoughts on this? >> Bristol Myers' TYK2 inhibitor succeeds in pair of Phase 3
psoriatic arthritis trials: Bristol Myers Squibb’s bet on TYK2 continued to pay off Monday,… >> Comment below! #strategy #competitiveintelligence #marketing #productmarketing #healthcare #pharma #pharmaceutical #biotech
psoriatic arthritis trials: Bristol Myers Squibb’s bet on TYK2 continued to pay off Monday,… >> Comment below! #strategy #competitiveintelligence #marketing #productmarketing #healthcare #pharma #pharmaceutical #biotech
Bristol Myers' TYK2 inhibitor succeeds in pair of Phase 3
psoriatic arthritis trials
Bristol Myers Squibb’s bet on TYK2 continued to pay off Monday, as Sotyktu passed two more Phase 3 tests in psoriatic arthritis, the company announced. Both pivotal trials met their primary endpoint, with Sotyktu inducing ...
dlvr.it
December 23, 2024 at 4:36 PM
Thoughts on this? >> Bristol Myers' TYK2 inhibitor succeeds in pair of Phase 3
psoriatic arthritis trials: Bristol Myers Squibb’s bet on TYK2 continued to pay off Monday,… >> Comment below! #strategy #competitiveintelligence #marketing #productmarketing #healthcare #pharma #pharmaceutical #biotech
psoriatic arthritis trials: Bristol Myers Squibb’s bet on TYK2 continued to pay off Monday,… >> Comment below! #strategy #competitiveintelligence #marketing #productmarketing #healthcare #pharma #pharmaceutical #biotech
first in clinic TYK2/JAK1 inhibitor targeting neuro inflammation for parkinson's enters ph II/III
ir.biohaven.com/news-release...
ir.biohaven.com/news-release...
Biohaven Enrolls First Patient into Phase 2/3 Trial in Early Parkinson's Disease, Targeting Neuroinflammation with Novel Brain-Penetrant TYK2/JAK1 Inhibitor | Biohaven, Ltd.
BHV-8000 is a first-in-clinic, brain-penetrant, and selective inhibitor of TYK2 and JAK1 kinases — a novel investigational therapy with the potential to treat the neuroinflammation and immune dysregul...
ir.biohaven.com
April 15, 2026 at 1:25 PM
first in clinic TYK2/JAK1 inhibitor targeting neuro inflammation for parkinson's enters ph II/III
ir.biohaven.com/news-release...
ir.biohaven.com/news-release...
🧬 July's most-read Genetics paper is an 'important' study that provides 'compelling' insights: elifesciences.org/articles/110...
Have a paper people should see? See what our Editors look for: elifesciences.org/about/aims-s...
Have a paper people should see? See what our Editors look for: elifesciences.org/about/aims-s...
Deep mutational scanning reveals pharmacologically relevant insights into TYK2 signaling and disease
A comprehensive mutational scan of TYK2 identifies novel allosteric sites, elucidates functional drug-protein interactions, and links autoimmune disease protection to reduced TYK2 protein abundance.
elifesciences.org
July 15, 2026 at 3:45 PM
🧬 July's most-read Genetics paper is an 'important' study that provides 'compelling' insights: elifesciences.org/articles/110...
Have a paper people should see? See what our Editors look for: elifesciences.org/about/aims-s...
Have a paper people should see? See what our Editors look for: elifesciences.org/about/aims-s...
Post hoc analysis of a phase 2b trial of zasocitinib (TYK2 inhibitor) for psoriatic arthritis showed reduction of plasma biomarkers related to TYK2 signaling response, inflammation, skin & joint pathogenesis, and cartilage/bone turnover
ACR Open Rheumatology
doi.org/10.1002/acr2...
ACR Open Rheumatology
doi.org/10.1002/acr2...
September 21, 2026 at 12:03 PM
Post hoc analysis of a phase 2b trial of zasocitinib (TYK2 inhibitor) for psoriatic arthritis showed reduction of plasma biomarkers related to TYK2 signaling response, inflammation, skin & joint pathogenesis, and cartilage/bone turnover
ACR Open Rheumatology
doi.org/10.1002/acr2...
ACR Open Rheumatology
doi.org/10.1002/acr2...